The device was returned to the manufacturer; however, there was no inlay found inside the container and no further analysis could be performed.The device history record review of the manufacturing lot was performed and there were no discrepancies or unusual findings related to the reported issue.Corneal haze and decreased vision are listed in the device labeling as known potential risks.Hypertension is a potential side effect of topical steroids (e.G., durezol), which are used to treat corneal haze.(b)(4).
|
The patient underwent implantation of the corneal inlay in the right eye on (b)(6) 2016.On (b)(6) 2016, corneal haze was first observed on the edge of the inlay.On (b)(6) 2017, the patient presented with grade 3 recurrent central corneal haze and the inlay was explanted on (b)(6) 2017.The haze was associated with a decrease in best corrected distance visual acuity (bcdva) from 20/20 (preoperatively) to 20/30 at onset, improving to 20/25 immediately prior to explant.One day post explant the corneal haze was resolving.The patient reported experiencing elevated blood pressure during the last 2 weeks of (b)(6).Additional information is being requested.
|